CPH Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Cipher Pharmaceuticals (TSE: CPH)
›
Cipher Pharmaceuticals (TSE: CPH) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 13.09 CAD on 19 November 2026, down 2.9% over 52 weeks. Its 52-week range is 12.76 CAD to 20.56 CAD: the price is 36.3% below the high and 2.6% above the low.
At a market capitalisation of 332.68M CAD, it trades at 7.2 times trailing earnings and 11.5 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 71% for CPH.
Cipher Pharmaceuticals reports return on equity of 21.6%, an operating margin of 49.1% and revenue down 1.0% year over year.
It holds more cash than debt, a net cash position of 14.68M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 18.38 CAD is 40.4% above the current price.